Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study

BACKGROUND: In a Phase III study, regdanvimab (CT-P59) reduced the risk of hospitalization or death versus placebo in patients with mild-to-moderate coronavirus disease 2019 (COVID-19). PURPOSE: We performed a retrospective cohort study of patients with COVID-19 to examine the effect of regdanvimab...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Young Rock, Oh, Yoon Ju, Kim, Jin Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109994/
https://www.ncbi.nlm.nih.gov/pubmed/35601976
http://dx.doi.org/10.1016/j.curtheres.2022.100675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109994/
https://www.ncbi.nlm.nih.gov/pubmed/35601976
http://dx.doi.org/10.1016/j.curtheres.2022.100675

Ejemplares similares